Company intelligence / Profile preview

KS Biomedix

Guildford, United Kingdom

Ownership: Private
Development stage: Other

Overview

KS Biomedix was a British biotechnology company specializing in the development of high-affinity monoclonal antibodies for the treatment of cancer and inflammatory diseases. The company was best known for its proprietary Sheep Monoclonal Antibody (SMAb) technology, which allowed for the creation of antibodies with significantly higher binding affinities than traditional murine or human counterparts. Its lead clinical candidate, TransMID (KSB 302), was a targeted toxin therapy for glioblastoma multiforme that reached Phase III trials. The company was acquired by Xenova Group in 2003 to bolster their oncology pipeline and antibody engineering capabilities.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyMonoclonal antibody fragmentFusion toxin protein therapyRecombinant protein
Industry: Biotech

Partnerships

SoseiNycomed

Beyond the preview

Go deeper on KS Biomedix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KS Biomedix.

Explore the full profile